2023-08-24 19:15:17 ET
More on Biogen
- Biogen Q2 2023 Analysis: Reata Acquisition, Financials, And Alzheimer's Prospects
- Biogen Inc. ( BIIB ) Q2 2023 Earnings Call Transcript
- Biogen And Alzheimer's Disease: Too Early To Celebrate
- Will Watershed Moment For Alzheimer's Propel Biogen Stock Higher?
- Biogen's Leqembi set for strong uptake based on Baird physician survey
- Sanofi was mystery suitor in Reata Pharma bidding war - report
- Biogen/ Sage expected to hike price for new depression drug after narrow label
- RBC Capital cuts Sage to sector perform, calls FDA decision "major setback"
- Seeking Alpha’s Quant Rating on Biogen
- Earnings data for Biogen
- Dividend for Biogen
For further details see:
FDA approves Sandoz's biosimilar of Biogen's blockbuster MS drug Tysabri